273 related articles for article (PubMed ID: 37616309)
1. Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer.
Shi D; Liang X; Li Y; Chen L
PLoS One; 2023; 18(8):e0290507. PubMed ID: 37616309
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression.
Huang X; Lin D; Lin S; Luo S; Huang X; Deng Y; Weng X; Huang P
Clin Breast Cancer; 2023 Jul; 23(5):508-518. PubMed ID: 37085377
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04.
Zhan M; Huang Z; Xu T; Xu X; Zheng H; Wu F
Front Public Health; 2023; 11():1049947. PubMed ID: 37457280
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.
Yang J; Han J; Zhang Y; Muhetaer M; Chen N; Yan X
Front Pharmacol; 2022; 13():924126. PubMed ID: 36160459
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States.
Peng Y; Wang L; Peng L; Liu Q; Yi L; Luo X; Li S; Qin S; Wan X; Tan C; Chen G
Clin Ther; 2023 Oct; 45(10):965-972. PubMed ID: 37537015
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
Paulissen JHJ; Seddik AH; Dunton KJ; Livings CJ; van Hulst M; Postma MJ; de Jong LA; Freriks RD
Eur J Health Econ; 2024 Jun; 25(4):689-699. PubMed ID: 37486557
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab deruxtecan
Zhu Y; Liu K; Zhu X; Qin Q; Zhu H
Front Pharmacol; 2022; 13():1025243. PubMed ID: 36386213
[No Abstract] [Full Text] [Related]
8. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.
Wang J; Yi Y; Wan X; Zeng X; Peng Y; Tan C
Adv Ther; 2022 Oct; 39(10):4583-4593. PubMed ID: 35943715
[TBL] [Abstract][Full Text] [Related]
9. Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States.
Lang Y; Wu B; Liu X
Breast Cancer (Dove Med Press); 2022; 14():453-463. PubMed ID: 36532255
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer.
Yang J; Han J; Zeng N; Yan X
Ther Adv Med Oncol; 2023; 15():17588359231169983. PubMed ID: 37228255
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis.
Zhu Y; Liu K; Wang M; Wang K; Zhu H
Breast; 2022 Dec; 66():191-198. PubMed ID: 36327624
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial.
Zheng Z; Chen H; Cai H; Xu S
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):387-395. PubMed ID: 38039117
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting.
Hu S; Wu Y; Luan J; Wang S; Fan G
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17933-17942. PubMed ID: 37964082
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States.
Mudumba R; Chan HH; Cheng YY; Wang CC; Correia L; Ballreich J; Levy J
Value Health; 2024 Feb; 27(2):153-163. PubMed ID: 38042333
[TBL] [Abstract][Full Text] [Related]
15. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
Le QA; Bae YH; Kang JH
Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Shi D; Li Y; Liang X; Chen L
Front Oncol; 2023; 13():1162360. PubMed ID: 37251935
[TBL] [Abstract][Full Text] [Related]
18. Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?
Wu W; Lin H; Cai J; Sun H; Liu J; Hu C; Wei X
Clin Drug Investig; 2023 Dec; 43(12):939-948. PubMed ID: 37975961
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.
Khoirunnisa SM; Suryanegara FDA; Setiawan D; Postma MJ; de Jong LA
PLoS One; 2024; 19(5):e0304483. PubMed ID: 38787899
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
